目的：分析双重黏弹剂DisCoVisc和透明质酸钠两种黏弹剂对白内障超声乳化摘除及折叠人工晶状体(IOL)植入术患者术后角膜内皮的影响。

方法：选取2017-06/2019-12在荆门市爱尔眼科医院就诊的白内障患者247例285眼，按随机数字表法分DisCoVisc组(123例141眼)与透明质酸钠组(124例144眼)。两组均接受超声乳化摘除及折叠IOL植入术，DisCoVisc组术中使用DisCoVisc作为黏弹剂，透明质酸钠组术中使用1.7%透明质酸钠作为黏弹剂； 比较两组术中超声乳化时间(UST)、累计释放能量(CDE)、植入IOL后抽吸黏弹剂的时间； 术后1d，1wk，1、3mo时角膜水肿情况，术前、术后3mo时的角膜内皮细胞密度(ECD)及ECD损失率，角膜内皮细胞面积变异系数(CV)、角膜六角形内皮细胞比率(6A)； 术前，术后1d，1wk，1mo时的眼压、裸眼视力≥0.5的患者比例及中央角膜厚度(CCT)值。

结果：两组UST、CDE、黏弹剂抽吸时间均无差异(P>0.05)； 两组术后1d时角膜水肿率无差异(P>0.05)，术后1wk时角膜水肿均消失； 术后3mo时DisCoVisc组ECD损失率显著低于透明质酸钠组(P<0.05)； 两组术前，术后1d，1wk，1mo时的眼压水平、裸眼视力≥0.5比例、CCT值均无差异(P>0.05)。

结论：Emery-Little晶状体核硬度分级Ⅱ～Ⅲ级患者超声乳化摘除联合折叠IOL植入术中使用DisCoVisc作为黏弹剂对角膜内皮的保护作用更好。

METHODS: A total of 247 patients(285 eyes)with cataract treated in Jingmen Aier Eye Hospital between June 2017 and December 2019 were selected, and they were divided into DisCoVisc group(123 cases, 141 eyes)and sodium hyaluronate group(124 cases, 144 eyes)by random number table method. Both groups were treated with phacoemulsification and foldable IOL implantation. DisCoVisc and 1.7% sodium hyaluronate were used as viscoelastic agents in DisCoVisc group and sodium hyaluronate group, respectively. The two groups were compared in terms of intraoperative ultrasound time(UST), cumulative dissipated energy(CDE), time for aspiration of viscoelastic agents after IOL implantation, corneal edema at 1d, 1wk, 1 and 3mo after operation, corneal endothelial cell density(ECD)and ECD loss rates before operation and at 3mo after operation, coefficient variation of corneal endothelial cell size(CV), percentage of corneal hexagonal endothelial cells(6A), intraocular pressure, the proportions of patients with uncorrected visual acuity ≥0.5 and central corneal thickness(CCT)values before and after operation at 1d, 1wk and 1mo.

RESULTS:There was no statistically significant difference between the two groups in UST, CDE, aspiration time of viscoelastic agents(P >0.05)or corneal edema both rate on day 1 after operation(P>0.05). Corneal edema disappeared at 1 wk after operation. The ECD loss rate in DisCoVisc group was significantly lower than that in sodium hyaluronate group at 3mo after operation(P<0.05). Intraocular pressure, the proportion of patients with uncorrected visual acuity ≥0.5 and CCT values showed no statistically significant differences between the two groups before and after operation at 1d, 1wk and 1mo(P >0.05).

CONCLUSION: DisCoVisc, as the viscoelastic agent in phacoemulsification and foldable IOL implantation for patients with Emery-Little grade Ⅱ-Ⅲ lens nucleus hardness, can better protect the patients' corneal endothelium.